16 September 2025   Franco-American CRO Genoskin  announces it has raised  $8.7M in its first funding round led by OCCTE (FPCI Occidev Impacts) to grow its human ex vivo skin platform.   In a field that struggles to bridge the gap between preclinical promise and clinical outcome, the project carried by Genoskin has a particular significance. The development of vaccines and therapies for human skin diseases is fraught with difficulties, not least of which is the existence of n